Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15074569 | 0.78 | SMN1; SMN2 (0.50) | NPC1RAB9AMAPTGABRR1SMN1; SMN2 | |
| SCHEMBL7104572 | 0.78 | GAA (0.54) | NPC1RAB9AMAPTGABRR1SMN1; SMN2 | |
| SCHEMBL2100653 | 0.75 | — | — | |
| SCHEMBL17732600 | 0.74 | SMN1; SMN2 (0.61) | NPC1RAB9AMAPTGABRR1SMN1; SMN2 | |
| SCHEMBL10552507 | 0.71 | NPSR1 (0.46) | NPC1RAB9AMAPTGABRR1SMN1; SMN2 | |
| SCHEMBL10821579 | 0.70 | ALDH1A1 (0.63) | NPC1RAB9AMAPTSMN1; SMN2GAA | |
| SCHEMBL4133844 | 0.70 | NPC1 (0.42) | NPC1RAB9AMAPTGABRR1SMN1; SMN2 | |
| SCHEMBL2588734 | 0.70 | — | — | |
| SCHEMBL11395633 | 0.70 | KDM4E (0.51) | NPC1RAB9AMAPTGABRR1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3448931 | 0.70 | KDM4E (0.51) | NPC1RAB9AMAPTGABRR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392503-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE | Regulus Therapeutics Inc. (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392503-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, PCSK7 | NPC1 1193/4885RAB9A 4047/4885MAPT 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.